This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
But as molecularbiology has advanced, so too has our approach to finding new drugs. Today, we're able to identify and target specific molecules involved in disease processes—a method that's much more like using a sniper rifle than throwing darts blindfolded. This method was more about serendipity than science.
Bhattacharyya wears many coats today, splitting his time between the Broad and the infectious disease ward at MGH, where a diagnostic method he developed at Broad is now being tested to see if it helps patients quickly receive the best antibiotics for their infections. A combined MD/PhD program offered both opportunities.
By creating genetically finagled mouse models and doing single cell RNA-sequencing, Feng and associates plant that Shp2 was needed by excrescence cells for HCC development, which validated and corroborated allowing that Shp2 presented an ideal target for new cancer curatives.
William Studier receives the 2024 Merkin Prize in ceremony at the Broad Institute for developing technology used to produce millions of doses of COVID-19 vaccines The groundbreaking, scalable technology is widely used in laboratories around the world today to efficiently produce large amounts of protein and RNA. Merkin (left) and F.
The only subject in school that held my interest was biology. As soon as I learned about DNA and RNA, I wanted to be a molecular biologist. I wanted to use molecularbiology to create drugs. Last stops at RNA My last roles in biotech were where my original passion began: DNA and RNA.
The implication of this work is that we have an unprecedented opportunity to advance a single tRNA medicine to unify treatment across a wide range of diseases with the same underlying genetic mutation, enabling us to provide medicines to patients, especially those with rare or ultra-rare diseases, with no or limited treatment options.
She has played a key role inbuilding the target identification platform and a proprietary database of transcriptome-wide, functional RNA structures. Having a combination of computational skills & scientific knowledge such as molecularbiology, genomics is also important.
When choosing my bachelor’s degree, the choice was between pursuing a career in biology or in computer science. Biology won that battle, and I pursued a bachelor’s and master’s degree in biochemistry and molecularbiology.
As a non-NSAID, it reduces adverse effects associated with these pain relief drugs, including kidney injury, GI gastritis/ulceration and blood pressure elevation, which can affect patients with cardiovascular disease and the elderly. We set out to improve health by developing a novel non-opioid that avoids potential abuse.
Norbert Makori and Pierre Jolicoeur: The Benefits of Combining Preclinical and Bioanalytical for Your Gene Therapy Studies pmjackson Fri, 03/01/2024 - 22:20 Recent advances in gene therapy have allowed for diseases to be approached differently. Gene therapy was first discovered in the 1960s, but only gained commercial interest in the 1980s.
CNGA3-achromatopsia is a hereditary disease that causes people to see in shades of gray. in Current Biology. They’re talking about a patient who has a rare genetic disease. ” Wellcome Collection , London I wrapped up my series on “30 Days of Great Biology Papers.” From Sulis D.B. in Science.
CNGA3-achromatopsia is a hereditary disease that causes people to see in shades of gray. in Current Biology. They’re talking about a patient who has a rare genetic disease. ” Wellcome Collection , London I wrapped up my series on “30 Days of Great Biology Papers.” From Sulis D.B. in Science.
But the technologies devised in the process of trying may revolutionize other areas of science, especially reproductive biology. Biology is a Burrito. The central dogma is often depicted as DNA→RNA→protein, but it’s much more: A biophysical marvel inside the smallest of vessels. 15 of 31.
A T4 phage can hold 171,000 bases of DNA or other molecules, including proteins and RNA. It uses single-molecule RNA fluorescence to measure mRNAs and fluorescent reporters to measure the proteins. The animals had a common disease variant, caused by a single amino acid substitution in the phenylalanine hydroxylase enzyme.
A T4 phage can hold 171,000 bases of DNA or other molecules, including proteins and RNA. It uses single-molecule RNA fluorescence to measure mRNAs and fluorescent reporters to measure the proteins. The animals had a common disease variant, caused by a single amino acid substitution in the phenylalanine hydroxylase enzyme.
What are the key findings of Circio’s in vivo proof-of-concept for its circVec circular RNA platform technology compared to conventional mRNA-based expression with DNA vectors? Circular RNA (circRNA) has two major advantages versus mRNA in a vector-expression context.
The intestine maintains a delicate balance in the body, absorbing nutrients and water while maintaining a healthy relationship with the gut microbiome, but this equilibrium is disrupted in parts of the intestine in conditions such as celiac disease, ulcerative colitis, and Crohn’s disease.
A clinical genomicist harnesses team-based science to help rare-disease patients By Allessandra DiCorato January 7, 2025 Breadcrumb Home A clinical genomicist harnesses team-based science to help rare-disease patients Heidi Rehm convinced labs and scientists to work together and share data.
By Matthew Cobb The Central Dogma is a linchpin for understanding how cells work, and yet it is one of the most widely misunderstood concepts in molecularbiology. Many students are taught that the Central Dogma is simply “DNA → RNA → protein.”
Journal of MolecularBiology (1961). Link Mathematical modeling and synthetic biology , by Chandran D. Drug Discovery Today: Disease Models (2008). Link Graphic Notations →Synthetic Biology Open Language Visual: An Open-Source Graphical Notation for Synthetic Biology , by Quinn J. . & Xie X.S.
Journal of MolecularBiology (1961). Link Mathematical modeling and synthetic biology , by Chandran D. Drug Discovery Today: Disease Models (2008). Link Graphic Notations →Synthetic Biology Open Language Visual: An Open-Source Graphical Notation for Synthetic Biology , by Quinn J. . & Xie X.S.
Amodei also imagines the ways AI could accelerate biological research and yield miraculous cures in the 21st century; everything from the prevention and treatment of nearly all infectious and inherited diseases to the elimination of most cancers. Biology experiments are also bottlenecked by the growth of organisms.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content